Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Genetic Counseling
Published in: Journal of Genetic Counseling 1/2017

01-02-2017 | Original Research

Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation

Authors: Adam H. Buchanan, Corrine I. Voils, Joellen M. Schildkraut, Catherine Fine, Nora K. Horick, P. Kelly Marcom, Kristi Wiggins, Celette Sugg Skinner

Published in: Journal of Genetic Counseling | Issue 1/2017

Login to get access

Abstract

Identifying unaffected women with a BRCA mutation can have a significant individual and population health impact on morbidity and mortality if these women adhere to guidelines for managing cancer risk. But, little is known about whether such women are adherent to current guidelines. We conducted telephone surveys of 97 unaffected BRCA mutation carriers who had genetic counseling at least one year prior to the survey to assess adherence to current guidelines, factors associated with adherence, and common reasons for performing and not performing recommended risk management. More than half of participants reported being adherent with current risk management recommendations for breast cancer (69 %, n = 67), ovarian cancer (82 %, n = 74) and both cancers (66 %, n = 64). Older age (OR = 10.53, p = 0.001), white race (OR = 8.93, p = 0.019), higher breast cancer genetics knowledge (OR = 1.67, p = 0.030), higher cancer-specific distress (OR = 1.07, p = 0.002) and higher physical functioning (OR = 1.09, p = 0.009) were significantly associated with adherence to recommended risk management for both cancers. Responses to open-ended questions about reasons for performing and not performing risk management behaviors indicated that participants recognized the clinical utility of these behaviors. Younger individuals and those with lower physical functioning may require targeted interventions to improve adherence, perhaps in the setting of long-term follow-up at a multi-disciplinary hereditary cancer clinic.
Literature
American Society of Clinical Oncology (2003). American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. Journal of Clinical Oncology, 21(12), 2397–2406. doi:10.​1200/​jco.​2003.​03.​189.CrossRef
Berliner, J. L., Fay, A. M., & Practice Issues Subcommittee of the National Society of Genetic Counselors’ Familial Cancer Risk Counseling Special Interest, G (2007). Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of genetic counselors. Journal of Genetic Counseling, 16(3), 241–260.CrossRefPubMed
Berliner, J. L., Fay, A. M., Cummings, S. A., Burnett, B., & Tillmanns, T. (2013). NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. Journal of Genetic Counseling, 22(2), 155–163.CrossRefPubMed
Botkin, J. R., Smith, K. R., Croyle, R. T., Baty, B. J., Wylie, J. E., Dutson, D., et al. (2003). Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet Part A, 118(3), 201–209.CrossRef
Bradbury, A. R., Ibe, C. N., Dignam, J. J., Cummings, S. A., Verp, M., White, M. A., et al. (2008). Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genetics in Medicine, 10(3), 161–166.CrossRefPubMedPubMedCentral
Buchanan, A. H., Skinner, C. E., Calingaert, B., Schildkraut, J. M., King, R. H., & Marcom, P. K. (2009). Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. Commun Oncol(6), 70–77.
Burke, W., Daly, M., Garber, J., Botkin, J., Kahn, M. J., Lynch, P., et al. (1997). Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer genetics studies consortium. JAMA, 277(12), 997–1003.CrossRefPubMed
Caiata-Zufferey, M., & Pagani, O. (2015). Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations. Genetics in Medicine, 17(9), 726–732. doi:10.​1038/​gim.​2014.​183.CrossRefPubMed
Calzone, K. A., Prindiville, S. A., Jourkiv, O., Jenkins, J., DeCarvalho, M., Wallerstedt, D. B., et al. (2005). Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer. Journal of Clinical Oncology, 23(15), 3455–3464.CrossRefPubMed
Caplan, L. S., McQueen, D. V., Qualters, J. R., Leff, M., Garrett, C., & Calonge, N. (2003). Validity of women’s self-reports of cancer screening test utilization in a managed care population. Cancer Epidemiology, Biomarkers & Prevention, 12(11 Pt 1), 1182–1187.
Chagpar, A. B., Polk Jr., H. C., & McMasters, K. M. (2008). Racial trends in mammography rates: a population-based study. Surgery, 144(3), 467–472.CrossRefPubMed
Claes, E., Evers-Kiebooms, G., Decruyenaere, M., Denayer, L., Boogaerts, A., Philippe, K., et al. (2005). Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behavioral Medicine, 31(3), 93–105.CrossRefPubMed
Finch, A., Beiner, M., Lubinski, J., Lynch, H. T., Moller, P., Rosen, B., et al. (2006). Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA, 296(2), 185–192.CrossRefPubMed
Finch, A. P., Lubinski, J., Moller, P., Singer, C. F., Karlan, B., Senter, L., et al. (2014). Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology, 32(15), 1547–1553.CrossRefPubMedPubMedCentral
Friebel, T. M., Domchek, S. M., Neuhausen, S. L., Wagner, T., Evans, D. G., Isaacs, C., et al. (2007). Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clinical Breast Cancer, 7(11), 875–882.CrossRefPubMed
Garcia, C., Wendt, J., Lyon, L., Jones, J., Littell, R. D., Armstrong, M. A., et al. (2014). Risk management options elected by women after testing positive for a BRCA mutation. Gynecologic Oncology, 132(2), 428–433.CrossRefPubMed
Hadley, D. W., Jenkins, J. F., Dimond, E., de Carvalho, M., Kirsch, I., & Palmer, C. G. (2004). Colon Cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. Journal of Clinical Oncology, 22(1), 39–44.CrossRefPubMed
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009). Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. Journal of Biomedical Informatics, 42(2), 377–381.CrossRefPubMed
Horowitz, M. J., Wilner, N., & Alvarez, W. (1979). Impact of event scale: a measure of subjective stress. Psychosomatic Medicine, 41(3), 209–218.CrossRefPubMed
Hsieh, H. F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. Qualitative Health Research, 15(9), 1277–1288.CrossRefPubMed
Hughes, C., Lerman, C., Schwartz, M., Peshkin, B., Wenzel, L., Narod, S., et al. (2002). All in the family: evaluation of the processand content of sisters’ communication about BRCA1 and BRCA2 genetic test results. American Journal of Medical Genetics, 107, 143–150.CrossRefPubMed
Julian-Reynier, C., Bouhnik, A. D., Mouret-Fourme, E., Gauthier-Villars, M., Berthet, P., Lasset, C., et al. (2010). Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics. Genetics in Medicine, 12(12), 801–807.CrossRefPubMed
Khoury, M. J., Coates, R. J., & Evans, J. P. (2010). Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence. Genetics in Medicine, 12(11), 680–683.CrossRefPubMed
King, E. S., Rimer, B. K., Trock, B., Balshem, A., & Engstrom, P. (1990). How valid are mammography self-reports? American Journal of Public Health, 80(11), 1386–1388.CrossRefPubMedPubMedCentral
Kinney, A. Y., Simonsen, S. E., Baty, B. J., Mandal, D., Neuhausen, S. L., Seggar, K., et al. (2006). Risk reduction behaviors and provider communication following genetic counseling and BRCA1 mutation testing in an African American kindred. Journal of Genetic Counseling, 15(4), 293–305.CrossRefPubMed
Kurian, A. W., Sigal, B. M., & Plevritis, S. K. (2010). Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. Journal of Clinical Oncology, 28(2), 222–231.CrossRefPubMed
Leonarczyk, T. J., & Mawn, B. E. (2015). Cancer risk management decision making for BRCA+ women. Western Journal of Nursing Research, 37(1), 66–84.CrossRefPubMed
Lerman, C., Hughes, C., Croyle, R. T., Main, D., Durham, C., Snyder, C., et al. (2000). Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Preventive Medicine, 31(1), 75–80.CrossRefPubMed
Lodder, L. N., Frets, P. G., Trijsburg, R. W., Meijers-Heijboer, E. J., Klijn, J. G., Seynaeve, C., et al. (2002). One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Research and Treatment, 73(2), 97–112.CrossRefPubMed
Meijers-Heijboer, E. J., Verhoog, L. C., Brekelmans, C. T., Seynaeve, C., Tilanus-Linthorst, M. M., Wagner, A., et al. (2000). Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet, 355(9220), 2015–2020.CrossRefPubMed
Meijers-Heijboer, H., Brekelmans, C. T., Menke-Pluymers, M., Seynaeve, C., Baalbergen, A., Burger, C., et al. (2003). Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology, 21(9), 1675–1681.CrossRefPubMed
Metcalfe, K. A., Birenbaum-Carmeli, D., Lubinski, J., Gronwald, J., Lynch, H., Moller, P., et al. (2008). International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer, 122(9), 2017–2022.CrossRefPubMedPubMedCentral
Miranda, P. Y., Tarraf, W., & Gonzalez, H. M. (2011). Breast cancer screening and ethnicity in the United States: implications for health disparities research. Breast Cancer Research and Treatment, 128(2), 535–542.CrossRefPubMed
Montano, D. E., & Phillips, W. R. (1995). Cancer screening by primary care physicians: a comparison of rates obtained from physician self-report, patient survey, and chart audit. American Journal of Public Health, 85(6), 795–800.CrossRefPubMedPubMedCentral
O’Neill, S. C., Valdimarsdottir, H. B., Demarco, T. A., Peshkin, B. N., Graves, K. D., Brown, K., et al. (2010). BRCA1/2 test results impact risk management attitudes, intentions, and uptake. Breast Cancer Research and Treatment, 124(3), 755–764.CrossRefPubMedPubMedCentral
Onwuegbuzie, A. (2003). Effect sizes in qualitative research: a prolegomenon. Quality & Quantity, 37(4), 393–409.CrossRef
Pal, T., Lee, J. H., Besharat, A., Thompson, Z., Monteiro, A. N., Phelan, C., et al. (2014). Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. Clinical Genetics, 85(1), 49–53.CrossRefPubMed
Patenaude, A. F., Dorval, M., DiGianni, L. S., Schneider, K. A., Chittenden, A., & Garber, J. E. (2006). Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. Journal of Clinical Oncology, 24(4), 700–706.CrossRefPubMed
Peshkin, B. N., Schwartz, M. D., Isaacs, C., Hughes, C., Main, D., & Lerman, C. (2002). Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiology, Biomarkers & Prevention, 11(10 Pt 1), 1115–1118.
Petrucelli, N., Daly, M. B., & Feldman, G. L. (2013). BRCA1 and BRCA2 hereditary breast and ovarian cancer. In R. A. Pagon, M. P. Adam, H. H. Ardinger, S. E. Wallace, A. Amemiya, L. J. H. Bean, T. D. Bird, C. T. Fong, R. J. H. Smith & K. Stephens (Eds.), GeneReviews(R). Seattle (WA): University of Washington, Seattle University of Washington, Seattle. All rights reserved.
Phillips, K. A., Jenkins, M. A., Lindeman, G. J., McLachlan, S. A., McKinley, J. M., Weideman, P. C., kConFab, I. (2006). Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clinical Genetics, 70(3), 198–206.
Rauscher, G. H., Johnson, T. P., Cho, Y. I., & Walk, J. A. (2008). Accuracy of self-reported cancer-screening histories: a meta-analysis. Cancer Epidemiology, Biomarkers & Prevention, 17(4), 748–757.CrossRef
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ‘t Veer, L., Garber, J. E., Weber, B. L. (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. Journal of Clinical Oncology, 22(6), 1055–1062.
Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute, 101(2), 80–87.CrossRefPubMedPubMedCentral
Riley, B. D., Culver, J. O., Skrzynia, C., Senter, L. A., Peters, J. A., Costalas, J. W., et al. (2012). Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of genetic counselors. Journal of Genetic Counseling, 21(2), 151–161.CrossRefPubMed
Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., Offit, K., & American Society of Clinical Oncology (2009). American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893–901..CrossRef
Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., et al. (2002). Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. Journal of Clinical Oncology, 20(5), 1260–1268.CrossRefPubMed
Schmeler, K. M., Sun, C. C., Bodurka, D. C., White, K. G., Soliman, P. T., Uyei, A. R.,. Lu, K. H. (2006). Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstetrics and Gynecology, 108(3 Pt 1), 515–520.CrossRefPubMed
Schwartz, M. D., Isaacs, C., Graves, K. D., Poggi, E., Peshkin, B. N., Gell, C., et al. (2012). Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer, 118(2), 510–517.CrossRefPubMed
Schwartz, M. D., Kaufman, E., Peshkin, B. N., Isaacs, C., Hughes, C., DeMarco, T., et al. (2003). Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. Journal of Clinical Oncology, 21(21), 4034–4041.CrossRefPubMed
Schwartz, M. D., Lerman, C., Brogan, B., Peshkin, B. N., Halbert, C. H., DeMarco, T., et al. (2004). Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. Journal of Clinical Oncology, 22(10), 1823–1829.CrossRefPubMed
Sidon, L., Ingham, S., Clancy, T., Clayton, R., Clarke, A., Jones, E. A., et al. (2012). Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. British Journal of Cancer, 106(4), 775–779.CrossRefPubMed
Skinner, C., Rawl, S., Moser, B., Buchanan, A., Scott, L., Champion, V., et al. (2005). Impact of the cancer risk intake system on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy. Journal of General Internal Medicine, 20(4), 360–365.CrossRefPubMed
Skinner, C. S., Buchanan, A., Champion, V., Monahan, P., Rawl, S., Springston, J., et al. (2011). Process outcomes from a randomized controlled trial comparing tailored mammography interventions delivered via telephone vs. DVD. Patient Educ Couns, 85(2), 308–312.CrossRefPubMed
Skinner, C. S., Tiro, J., & Champion, V. L. (2015). The health belief model. In K. Glanz, B. K. Rimer, & K. Viswanath (Eds.), Health Behavior Theory, Research, and Practice (5th ed., pp. 75–94). San Francisco, CA: Jossey-Bass.
Spielberger, C. D., Gorsuch, R., Lushene, R., & al., e. (1983). State-Trait Anxiety Inventory for Adults: Sampler Set - Manual, Test, Scoring Key. Palo Alto, CA: Mind Garden.
Tinley, S. T., Houfek, J., Watson, P., Wenzel, L., Clark, M. B., Coughlin, S., et al. (2004). Screening adherence in BRCA1/2 families is associated with primary physicians’ behavior. American Journal of Medical Genetics. Part A, 125A(1), 5–11.CrossRefPubMed
Trepanier, A., Ahrens, M., McKinnon, W., Peters, J., Stopfer, J., Grumet, S. C., et al. (2004). Genetic cancer risk assessment and counseling: recommendations of the National Society of genetic counselors. Journal of Genetic Counseling, 13(2), 83–114.CrossRefPubMed
Uyei, A., Peterson, S. K., Erlichman, J., Broglio, K., Yekell, S., Schmeler, K.,. Arun, B. (2006). Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer, 107(12), 2745–2751.CrossRefPubMed
Ware Jr., J., Kosinski, M., & Keller, S. D. (1996). A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care, 34(3), 220–233.CrossRefPubMed
Warner, E., Hill, K., Causer, P., Plewes, D., Jong, R., Yaffe, M., et al. (2011). Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. Journal of Clinical Oncology, 29(13), 1664–1669.CrossRefPubMedPubMedCentral
Watson, M., Kash, K. M., Homewood, J., Ebbs, S., Murday, V., & Eeles, R. (2005). Does genetic counseling have any impact on management of breast cancer risk? Genetic Testing, 9(2), 167–174.CrossRefPubMed
Willis, G. B. (2005). Cognitive interviewing. Thousand Oaks, CA: SAGE Publications.CrossRef
Yerkes, R. M., & Dodson, J. D. (1908). The relation of strength of stimulus to rapidity of habit-formation. Journal of Comparative Neurology and Psychology, 18, 459–482.CrossRef
Zapka, J. G., Bigelow, C., Hurley, T., Ford, L. D., Egelhofer, J., Cloud, W. M., et al. (1996). Mammography use among sociodemographically diverse women: the accuracy of self-report. American Journal of Public Health, 86(7), 1016–1021.CrossRefPubMedPubMedCentral
Metadata
Title
Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation
Authors
Adam H. Buchanan
Corrine I. Voils
Joellen M. Schildkraut
Catherine Fine
Nora K. Horick
P. Kelly Marcom
Kristi Wiggins
Celette Sugg Skinner
Publication date
01-02-2017
Publisher
Springer US
Published in
Journal of Genetic Counseling / Issue 1/2017
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-016-9981-6

Other articles of this Issue 1/2017

Journal of Genetic Counseling 1/2017 Go to the issue

Original Research

Men’s Knowledge About Maternal Serum Screening for Down Syndrome and their Attitude Towards Amniocentesis

Original Research

Attitudes Toward Discussing Approved and Investigational Treatments for Cystic Fibrosis in Prenatal Genetic Counseling Practice

Original Research

Health Behaviors and their Relationship with Disease Control in People Attending Genetic Clinics with a Family History of Breast or Colorectal Cancer

Original Research

“The Top Priority Is a Healthy Baby”: Narratives of Health, Disability, and Abortion in Online Pregnancy Forum Discussions in the US and China

Professional Issues

Ancestry Testing and the Practice of Genetic Counseling

Professional Issues

A Retrospective Exploration of the Impact of the ‘Angelina Jolie Effect’ on the Single State-Wide Familial Cancer Program in Perth, Western Australia